Comparison of ESC and ACCF/AHA Guidelines for Oral Antiplatelet Treatment in the Management of Patients with Acute Coronary Syndrome

Basically, acute coronary syndrome (ACS) is caused by the partial or total occlusion of coronary arteries because of platelet activation and aggregation. Hence, one of the major components of ACS treatment is the inhibition of platelet activation and aggregation. New studies performed in recent year...

Full description

Bibliographic Details
Published in:	Eurasian Journal of Emergency Medicine
Main Authors:	Ayhan Sarıtaş, Harun Güneş
Format:	Article
Language:	English
Published:	Emergency Medicine Physicians’ Association of Turkey 2016-09-01
Subjects:	Acute coronary syndrome recommendations aspirin prasugrel ticagrelor clopidogrel
Online Access:	http://akademikaciltip.com/archives/archive-detail/article-preview/comparison-of-esc-and-accf-aha-guidelines-for-oral/21815

Similar Items

Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines
by: Georges Jourdi, et al.
Published: (2022-04-01)

Double antiplatelet therapy in patients with acute coronary syndrome
by: A. V. Rodionov, et al.
Published: (2011-10-01)

Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020-12-01)

Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials
by: Vincent Roule, et al.
Published: (2017-02-01)

Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01)

Dual Antiplatelet Therapy in Coronary Artery Disease
by: Raghav Sharma, et al.
Published: (2020-08-01)

Optimal dual antiplatelet therapy for coronary artery bypass grafting: a systematic review and meta-analysis
by: Ali Salman, et al.
Published: (2025-03-01)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
by: Larisa H. Cavallari, et al.
Published: (2018-04-01)

How to undertake procedures while on antiplatelet agents: a hematologist's view
by: Dawn Swan, et al.
Published: (2024-08-01)

Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020
by: Mohammed Essa, et al.
Published: (2023-04-01)

Vorapaxar
by: Gianluca Airoldi, et al.
Published: (2013-04-01)

Should aspirin be replaced with ADP blockers and anti-GPVI to manage thrombosis?
by: Hafsa Khan, et al.
Published: (2023-01-01)

Ticagrelor
by: Gianluca Airoldi, et al.
Published: (2013-03-01)

Extended dual antithrombotic therapy in patients with chronic coronary syndrome — which agent should be added to aspirin?
by: Jacek Kubica, et al.
Published: (2025-06-01)

Inflammation and platelet reactivity during adjunctive colchicine versus aspirin in patients with acute coronary syndrome treated with potent P2Y12 inhibitor
by: Seung-Yul Lee, et al.
Published: (2024-04-01)

Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines
by: Jacek Kubica, et al.
Published: (2020-12-01)

Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients
by: Rebecca Gosling, et al.
Published: (2017-11-01)

Comparative effectiveness and safety of prasugrel and ticagrelor in patients of acute coronary syndrome undergoing percutaneous transluminal coronary angioplasty: A propensity score-matched analysis
by: Avik Ray, et al.
Published: (2024-03-01)

Use of antiplatelet agents in patients after myocardial infarction followed up in Moscow outpatient clinics. Results of a non-interventional prospective study
by: A. I. Sapina, et al.
Published: (2024-04-01)

Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk
by: O. V. Averkov
Published: (2021-02-01)

Clopidogrel in the treatment of patients with ST-elevation acute myocardial infarction: state-of-art in 2013
by: O. V. Averkov
Published: (2013-02-01)

Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention
by: I. N. Dyakov, et al.
Published: (2020-09-01)

Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis
by: Gerhard Selhorst, et al.
Published: (2019-04-01)

ANTIPLATELET THERAPY OF ACUTE CORONARY SYNDROME: CURRENT CAPAB ILITIES
by: E. V. Konstantinova, et al.
Published: (2018-07-01)

Review of the Ticagrelor Trials Evidence Base
by: Grace C. Herron, et al.
Published: (2024-06-01)

Prasugrel
by: Gianluca Airoldi, et al.
Published: (2013-04-01)

Antiplatelet Therapy in Chronic Coronary Artery Disease Patients With a History of Angioplasty. When is Aspirin Not Enough? A Systematic Review
by: Stylianos Fiflis, et al.
Published: (2025-09-01)

Dual Antiplatelet Therapy with Parenteral P2Y<sub>12</sub> Inhibitors: Rationale, Evidence, and Future Directions
by: Giulia Alagna, et al.
Published: (2023-04-01)

Dual versus single antiplatelet therapy in patients with nonminor ischemic stroke: a meta-analysis
by: Izabela Orlandi Môro, et al.
Published: (2025-02-01)

Dual antiplatelet therapy for reduction in mortality in patients with acute and chronic coronary syndromes
by: Maciej Lesiak, et al.
Published: (2021-12-01)

Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS
by: Benedikt S. Biesinger, et al.
Published: (2021-05-01)

Clopidogrel Adherence to AHA/ACC Guideline in Patients with Open Heart Surgery in a Tertiary Heart Center
by: Naser Safaie, et al.
Published: (2019-09-01)

Effects of remnant cholesterol on the efficacy of genotype-guided dual antiplatelet in CYP2C19 loss-of -function carriers with minor stroke or transient ischaemic attack: a post-hoc analysis of the CHANCE-2 trialResearch in context
by: Anxin Wang, et al.
Published: (2024-01-01)

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
by: V. A. Sulimov, et al.
Published: (2015-12-01)

Sex-Related Differences in On-Treatment Platelet Reactivity in Patients with Acute Coronary Syndrome
by: David Mutschlechner, et al.
Published: (2025-08-01)

EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?
by: Roman M. Shakhnovich
Published: (2018-12-01)

Real‐World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
by: Mustafa Yildirim, et al.
Published: (2023-08-01)

Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE‐ACS) Study
by: Amit N. Vora, et al.
Published: (2016-09-01)

Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study
by: Hua Yan, et al.
Published: (2020-06-01)

Efficacy and safety of mono antiplatelet therapy with colchicine in acute coronary syndrome patients following percutaneous coronary intervention: rationale and design of the MACT II trial
by: Ji Yong Jang, et al.
Published: (2025-10-01)